Bank of America’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-168,202
| Closed | -$5.79M | – | 7602 |
|
|
2020
Q3 | $5.79M | Sell |
168,202
-495,928
| -75% | -$10.6M | ﹤0.01% | 2776 |
|
|
2020
Q2 | $11.1M | Buy |
664,130
+249,675
| +60% | +$4.24M | ﹤0.01% | 2123 |
|
|
2020
Q1 | $5.97M | Sell |
414,455
-24,645
| -6% | -$630K | ﹤0.01% | 2500 |
|
|
2019
Q4 | $14.7M | Buy |
439,100
+112,886
| +35% | +$3.16M | ﹤0.01% | 2177 |
|
|
2019
Q3 | $6.83M | Buy |
326,214
+69,392
| +27% | +$1.42M | ﹤0.01% | 2899 |
|
|
2019
Q2 | $5.35M | Sell |
256,822
-25,737
| -9% | -$530K | ﹤0.01% | 3168 |
|
|
2019
Q1 | $6.32M | Sell |
282,559
-248,496
| -47% | -$5.85M | ﹤0.01% | 2924 |
|
|
2018
Q4 | $12.7M | Buy |
531,055
+13,679
| +3% | +$354K | ﹤0.01% | 2063 |
|
|
2018
Q3 | $14.1M | Buy |
517,376
+223,270
| +76% | +$6.31M | ﹤0.01% | 2134 |
|
|
2018
Q2 | $7.91M | Buy |
294,106
+48,048
| +20% | +$1.47M | ﹤0.01% | 2689 |
|
|
2018
Q1 | $7.83M | Buy |
246,058
+52,635
| +27% | +$1.85M | ﹤0.01% | 2648 |
|
|
2017
Q4 | $7.31M | Sell |
193,423
-84,943
| -31% | -$2.74M | ﹤0.01% | 2763 |
|
|
2017
Q3 | $6.9M | Buy |
278,366
+69,874
| +34% | +$1.51M | ﹤0.01% | 2892 |
|
|
2017
Q2 | $4.29M | Buy |
208,492
+16,607
| +9% | +$317K | ﹤0.01% | 3185 |
|
|
2017
Q1 | $4.17M | Buy |
191,885
+47,378
| +33% | +$972K | ﹤0.01% | 3202 |
|
|
2016
Q4 | $2.96M | Buy |
144,507
+8,060
| +6% | +$165K | ﹤0.01% | 3422 |
|
|
2016
Q3 | $2.05M | Buy |
136,447
+2,167
| +2% | +$29.3K | ﹤0.01% | 3617 |
|
|
2016
Q2 | $1.45M | Sell |
134,280
-11,140
| -8% | -$151K | ﹤0.01% | 3882 |
|
|
2016
Q1 | $1.97M | Buy |
145,420
+129,842
| +833% | +$2.03M | ﹤0.01% | 3580 |
|
|
2015
Q4 | $287K | Buy |
15,578
+6,959
| +81% | +$129K | ﹤0.01% | 5146 |
|
|
2015
Q3 | $218K | Buy |
+8,619
| New | +$202K | ﹤0.01% | 5289 |
|
Bank of America's AIMT Position: Q4 2020 in Review
Bank of America sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 168,202 shares — an estimated $5.79M sold.
Bank of America first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $14.7M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Bank of America reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Bank of America sold 168,202 Aimmune Therapeutics shares in Q4 2020, an estimated $5.79M.
- Bank of America first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
- Bank of America's Aimmune Therapeutics position peaked at $14.7M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Bank of America's 13F filing for Q4 2020, filed 10 Feb 2021.